Inhibrx Q3 net loss widens on higher G&A expenses
INBX•Inhibrx reported a third-quarter net loss of $38.73 million, slightly below analyst estimates, as higher G&A expenses offset lower R&D costs. Loss per share was $2.46, and the company recognized $2 million in license fee revenue from its Pfizer agreement.
1. Quarterly results
Inhibrx reported a third-quarter net loss of $38.73 million, compared with analyst estimates of $38.85 million. Loss per share was $2.46, beating the $2.52 estimate. Operating expenses totaled $33.74 million, while operating loss was $31.74 million.
2. Costs and outlook
Research and development expenses fell as clinical trial costs and headcount declined, partly offset by higher contract manufacturing expenses. General and administrative expenses rose due to pre-commercialization activities for ozekibart, and other expenses increased mainly on higher interest expense. The company expects initial Phase 2 results for ordastobart in head and neck squamous cell carcinoma and perioperative non-small cell lung cancer around mid-2027.
